KKR-Led Consortium to Invest Up to $2.21 Billion in ST Telemedia Global Data Centres
By Don Nico Forbes
ST Telemedia Global Data Centres will raise up to S$2.99 billion, equivalent to $2.21 billion, from a KKR-led consortium with Singapore Telecommunications, in Southeast Asia's largest digital-infrastructure investment of 2024.
The companies said Tuesday that the transaction comprises an initial S$1.75 billion investment via redeemable preference shares, with detachable warrants. Upon exercise of the warrants in full, the consortium will invest an extra S$1.24 billion, they said.
Proceeds of the investment will be used to further advance ST Telemedia's market position, and to support its continuing international expansion and growth plans.
ST Telemedia is a data center provider with more than 95 data centers across 11 geographies, with headquarters in Singapore.
"With the industry experiencing unprecedented cloud and AI-led growth, this strategic partnership with KKR and Singtel will be a significant catalyst for STT GDC's next chapter of growth," ST Telemedia Chief Executive Bruno Lopez said.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
June 18, 2024 07:54 ET (11:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks